Article
Lysostaphin-resistant variants of Staphylococcus aureus demonstrate reduced fitness in vitro and in vivo.
Antimicrobial agents and chemotherapy - 1 Feb 2007
Kusuma Caroline, Jadanova Anna, Chanturiya Tanya, Kokai-Kun John F
Abstract excerpt
Lysostaphin is under development as a therapy for serious staphylococcal infections. During preclinical development, lysostaphin-resistant Staphylococcus aureus variants have occasionally been reported in vitro and in vivo. The acquisition of resistance to this drug, however, leads to a significant increase in beta-lactam antibiotic susceptibility, rendering methicillin-resistant S. aureus (MRSA) strains...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
